KEY TAKEAWAYS
- The study aimed to evaluate how CD19-directed CAR T cell therapy enhances outcomes for NHL patients while investigating associated toxicities.
- The findings provided the first analysis of CAR T product toxicities, leading to improved toxicity predictions and individualized therapies.
CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for many non-Hodgkin B cell lymphoma (NHL) patients, though associated toxicities can be severe and unpredictable.
Samuel Yamshon and his team spearheaded a study that aimed to assess how CD19-targeted CAR T cell therapy enhances outcomes in NHL patients and explore associated unpredictable and severe toxicities.
This systematic review and meta-analysis aimed to identify potential variations in prevalent toxicities, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, and infections, among commercially available CAR T products for NHL treatment.
Following a rigorous study selection process, a cohort of 1,364 patients across 15 prospective clinical trials investigating axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel) was utilized.
Researchers observed that axi-cel exhibited significantly higher rates of CRS and ICANS than liso-cel and tisa-cel. Conversely, liso-cel demonstrated significantly greater rates of all-grade and severe neutropenia. Although febrile neutropenia and all-grade infection rates did not differ significantly between products, the incidence of severe infection was elevated with axi-cel.
The study initially delineated toxicity profiles linked to different CAR T products. This understanding could enable personalized therapy and early anticipation of toxicities. No funding information was available.
Source: https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(24)00066-1/abstract
Yamshon S, Gribbin C, Alhomoud M, et al. (2024) ‘’Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.’’ Clinical Lymphoma Myeloma and Leukemia, DOI: https://doi.org/10.1016/j.clml.2024.02.007.
